China’s pharmaceutical drug market is constantly growing and is the second-largest pharmaceutical industry in the world, after the United States. It is estimated to reach $161.8 billion by 2023, with an average growth rate of 5% in the coming years, taking a 30% share of the global market. The acceleration of new drug access, changing […]

Read More →

Sourcing or importing the IMPs and their supportive products is a challenging process for many researchers and this is more prominent with the countries like Japan and China where understanding the regulatory is difficult due to the language barriers and rapid changing norms for making imports.  Many key players in logistics are unclear about the […]

Read More →

As clinical trials have become increasingly global and complex, ancillaries have grown in volume, type, and expectations. The clinical trials supplies market is projected to reach  USD 2.5 billion by 2025 owing to the logistics services with the increasing number of clinical trials involving temperature-sensitive drugs. Currently, North America is the largest market for clinical […]

Read More →

Clinical trials in rare diseases are more challenging than clinical trials in more frequent diseases for many factors such as the trial design, the number of patient populations available for recruitment, require regulatory support, etc. Applying a perfect clinical development strategy may help in overcoming these challenges and accelerate the drug development process in Orphan […]

Read More →

China has brought significant reforms in its regulatory system for pharmaceutical industry and clinical trials. In its continuous drive to improve the system, recently China’s Food and Drug Administration (CFDA) announced a major overhaul of its medical device regulations as well. To the current regulations, China has made significant changes. Summarily, 12 articles were newly […]

Read More →